. More than half a century later, we have come a long way in our understanding of the molecular basis of epigenetics and its role in cellular and organismal plasticity and dynamics. Several ground-breaking studies have revealed that alterations to chromatin -the nuclear complex of macromolecules that consists of DNA, protein (histones) and RNA -can in some cases account for changes in gene expression (for a selection of classic experiments concerning DNA methylation see BOX 1) . For the purposes of this Review, we therefore define modifications of DNA and histones as alterations to chromatin but distinguish between chromatin marks (individual chemical modifications) and features ( multiple linked modifications and more complex elements).
Catalogues of chromatin marks and features obtained from cells and tissues at different stages of development and disease states have become an extremely useful resource. Epigenomic profiling was the key to discovering many significant associations between chromatin features and genomic function at the level of gene regulation and expression, cell identity, ageing and even disease [4] [5] [6] . However, correlation does not necessarily imply causation, and technical limitations had not previously allowed the interrogation of individual marks or combinations of marks to test for direct functional effects. Consequently, the majority of research focused on identifying what Adrian Bird defined as the unifying definition of epigenetic events: "the structural adaptation of chromo somal regions" that may "register, signal or perpetuate altered activity states" (REF. 7 ). Epigenetic research is currently at a turning point. New approaches, which benefit from the remarkable developments in genome editing, enable us to move forward and to finally elucidate which individual chromatin marks or features have causal roles in processes such as gene regulation, cellular memory, cellular differentiation and disease aetiology 8 . The terms 'function' and 'functional' mean different things to different people and, in our view, are at times used incorrectly in the literature. For clarification and in the context of this Review, we therefore differentiate between two levels of function -inferred and causalas illustrated in FIG. 2. Inferred function is usually based on the correlation of aggregated marks or features with observed effects, for example, gene activity states or phenotypes, but cannot establish whether marks have truly causal roles. By contrast, causal function is based on direct evidence of individual marks or features driving the expression of a particular gene or regulating a particular phenotype.
Throughout this Review, we emphasize the level of function that can or that has been demonstrated using different experimental approaches. We discuss what can be learned from comparative chromatin profiling, and how associations of chromatin marks with phenotypes can identify candidate regions for functional testing. Although we fully appreciate the importance of plant epigenomics and associated resources [9] [10] [11] [12] [13] , this Review focuses on mammalian chromatin. We briefly revisit insights gained from early knockout studies but mainly concentrate on recent epigenome editing approaches 14 (sometimes also known as epigenetic engineering 15 ), which directly test causality. A short overview of methods for epigenome editing will be provided. However, for a more detailed discussion of technological aspects, we refer the reader to excellent recent reviews on genome and epigenome editing [16] [17] [18] . Finally, we speculate how these approaches could be used to efficiently deduce causal function from profiles in the future. Although we recognize the importance of differential expression and the binding of transcription factors, nucleosome positioning and chromatin remodelers to gene regulation (which have previously been thoroughly reviewed) [19] [20] [21] , we mostly focus on the contribution of chromatin marks to gene expression.
Epigenomic resources
Following the completion of the Human Genome Project 22 it became immediately evident that additional efforts would be required to understand how complex genomes are regulated. Driven by different technologies, new international resources (see Further information) were soon established to profile all aspects of the genome and epigenome that were thought to have functional rele vance. Collectively, these resources have increased the amount of data per sample that we now have over and above the genome by several orders of magnitude.
Projects and data types. Beginning in 2003, ENCODE (Encyclopedia of DNA Elements) was the first international project to use large-scale epigenomic profiling to identify regulatory elements in the human genome.
ENCODE pioneered many of the required technologies (for example, for profiling histone modifications) and focused on cell lines rather than tissues or primary cells. The project was subsequently expanded to include model organisms (modENCODE), adding the power of comparative epigenomics. ENCODE became a member of the International Human Epigenome Consortium (IHEC), a project that was launched in 2010 and which aims to generate 1,000 reference epigenomes in primary tissues and cell types and which has become the umbrella organization under which national and international epigenome efforts are jointly coordinated. IHEC currently has nine members, ENCODE (United States), Roadmap Epigenomics (United States), BLUEPRINT (European Union), DEEP (Germany), Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC; Canada) and the national epigenome projects from Japan, Korea, Singapore and Hong Kong (see Further information). Within the context of this Review, the key IHEC achievements so far have been the introduction and the implementation of the IHEC quality standards for epigenomic data and the IHEC data portal, which provides access to the data of all IHEC projects. At the time of writing, more than 7,000 data sets from more than 350 tissues and cell types were available, including 294 complete and 1,643 partially complete reference epigenomes. Based on highly successful pilot projects 23 , these data will soon be complemented by a new international effort (4D Nucleome), which aims to produce three-dimensional maps of mammalian genomes and to develop predictive models to infer function from mammalian genome architecture. As discussed below, the integration of epigenomic features with genetic variation (for example, from the Catalogue of published Genome-wide association studies (GWAS) . Studies that aim to identify genetic loci associated with an observable trait, disease or condition.
Single-nucleotide polymorphisms
(SNPs). Single base-pair differences in the DNA sequence between individual members of a species.
DNase I-hypersensitive sites (DHSs). Regions of chromatin that are sensitive to digestion with DNase I, indicating that these sites are accessible and free of nucleosomes.
genome-wide association studies (GWAS Catalogue)), gene expression (for example, from the GenotypeTissue Expression (GTEx) project) and other data is tremendously useful for pinpointing candidate variants for functional analysis. However, one limitation that currently hampers the comprehensive exploitation of these resources for functional and other analyses is that much of the raw data are not available under open access and require prior approval by a Data Access Committee (DAC).
The descriptive data types that can be obtained by epigenomic profiling are still growing in both numbers and complexity. BOX 2 illustrates this complexity of profiles and provides details of the different marks and features profiled to date. These can be divided into the following categories: DNA modifications, which includes C5-methylcytosine (5 mC), the first and most well-studied epigenomic modification that was discovered in 1948 (REF. 24 ), as well as N6-methyladenine (6 mA), which was only recently reported 25 . Accounting for oxidation products of 5 mC, as well as 3 mC and 6 mA, there are currently six different known epigenomic modifications at the DNA level but this number is likely to increase in the future, and analysis of their chemical and biological functions is subject to intense ongoing research 26, 27 . Histone modifications represent by far the largest category among profiled chromatin marks. With 12 currently known chemical modifications, which can occur at more than 130 post-translational modification sites 28 on five canonical and some 30 histone variants, the theoretical number of combinatorial possibilities is truly astronomical 29 , and, consequently, our knowledge of their functional roles is still limited 30, 31 . For some commonly studied marks, however, correlations between their presence and the activity of different genomic elements are apparent (for example, methylation of H3K9 and H3K27 at inactive (or poised) promoters, methylation of H3K4 and acetylation of H3K27 on active enhancers and promoters, and methylation of H3K36 in transcribed gene bodies; for a more comprehensive view, see the 'dashboard' of histone modifications from Zhou and colleagues 30 ). Profiling of nucleosome occupancy along the genome can reveal regions of open chromatin that may have gene regulatory functions. Interestingly, common trait-associated single-nucleotide polymorphisms (SNPs) identified through GWAS approaches frequently lie outside of coding regions but fall into DNase I-hypersensitive sites (DHSs), where they are thought to regulate distal genes 32 . Profiling of RNA modifications on coding and non-coding RNAs is less advanced, owing to technological limitations. Although more than 100 different RNA modifications are known 33 , new modifications are continuing to be discovered [34] [35] [36] and they have not yet been comprehensively profiled across the transcriptome 33, 37 . Further advanced is the systematic profiling of chromatin architecture, which only recently became technically and economically feasible. Projects, such as the 4D Nucleome (mentioned above), aim to link genetic and epigenomic variants with the enhancers and promoters that they interact with in three-dimensional space, thereby defining gene-set interactomes and pathways as new candidates for functional analysis and therapeutic targeting. Such local short-range interactions have been shown to aggregate into higher-order chromatin domains, which can themselves have functional roles 38 .
Data integration and interpretation.
A wide variety of different marks and features have been profiled, resulting in an amount of published epigenomic data that can easily be overwhelming. Taken together, comparative approaches have resulted in reliable information about the composition and plasticity of mammalian epigenomes during development and disease. However, without additional context, it remains difficult to predict from these descriptive data which of the large number of marks, features and profiles are the most indicative for causal and quantitative effects (FIG. 2) . Consequently, next-generation approaches for the integration and interpretation of chromatin features have attracted great interest. IHEC, for example, has identi fied a subset of nine profiles and assays (BOX 2) that are required for the generation of so-called reference epi genomes in order to bundle obtained epigenomic data and to maximize the potential of these data to infer function. The rapidly growing number of reference epigenomes registered in EpiRR (see Further information) constitutes an ideal starting point for integrative analysis. Recent approaches using high-level epi genomic data integration have been pioneered by the Roadmap Epigenomics Project and have so far been applied to 111 human epigenomes 39 . Typically, such integrated data sets consist of 20-50 genome-wide profiles making up a multidimensional data matrix, as illustrated in FIG. 3 . To ensure consistency across the matrix, novel methods such as ChromImpute have been developed for largescale imputation of epigenomic data 40 , resulting in several improvements: the detection of low-quality data, the inference of missing data, and, as a consequence, a more accurate and complete annotation and interpretation of epigenomes.
Box 1 | DNA methylation: key early experiments to address function
Chromatin can be altered in a large variety of ways, but only a few chromatin features have been shown to be functionally involved in gene expression. The first chromatin mark to gain attention (and which is still the best-studied) was DNA methylation. Discovered in the late 1940s as a modification of cytosine bases 24, 118 it early on became a prime candidate for an epigenetic effector because of its uneven distribution in the genome and its heritability [119] [120] [121] . The first correlations between gene expression and DNA methylation were reported on a series of highly informative model loci (including chicken and mammalian globin genes, the X-chromosome inactivation centre (XIC), regions subjected to genomic imprinting, and virus, transgene or retrovirus silencing) [122] [123] [124] . However, it was only after experimental inhibition 125 or deletion of DNA methyltransferases 126 , in vitro methylation of DNA 127 and genetic deletion of differentially methylated regions 51 , that functional connections could be deduced. Because of epigenomics and transcriptomics we know now that the relationship between DNA methylation and gene expression is probably more complicated than initially suspected. Although marks at certain positions correlate with the silencing of some genes (for example, in colon cancer) 128 , others are rather uninformative or even occur at active genes [129] [130] [131] [132] .
Hi-C
Experimental method to map contacts formed between segments of DNA in three-dimensional space on a genome-wide scale.
CRISPR-Cas9
(Clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9). Components of a bacterial defence system against viruses.
For the interpretation of such complex data, multidimensional matrices can be aggregated or collapsed into a small number of chromatin states using computational programs such as ChromHMM 41 and Segway 42, 43 , which have been trained on a variety of data sets. These data integration methods produce chromatin states that can be annotated with inferred function (including 'promoter' , 'enhancer' , 'insulator' , 'transcribed' and 'repressed') at a particular genomic locus. Several of such inferred enhancers that are defined by strong H3K4 methylation and weak signals of RNA polymerase II (RNAPII) occupancy have been experimentally validated 41 . Furthermore, chromatin states have also been used in combination with Hi-C interaction maps to predict individual and cell type-specific enhancer-promoter interactions using TargetFinder 44 . On the basis of these and many more specialized tools such as Epigram, epiGRAPH, Epilogos, eFORGE, Epigwas, ChromNet and the Epigenetic Clock (see Further information), complex chromatin maps can be further segmented.
In the context of disease, recent examples using integrative epigenomic analysis include the discovery of pathogenic rewiring of cell type-specific enhancer circuits in obesity 45 and type 1 diabetes 46 , as well as the finding that epigenomic changes accompany innate immunity in humans 47 . Of these, the first study 45 best exemplifies the profiles-to-function approach (known as P2F) presented in this Review. Using integrative ana lysis (as illustrated in FIG. 3) the authors predicted the cell type and regulatory element (enhancer) in and through which a genetic variant that was identified by GWAS was likely to exert its function in fat mass and obesity (FTO)-associated obesity. They achieved this by mapping GWAS-identified risk variants onto chromatin state annotations that were generated by profiling 127 human cell types to predict the regulatory nature of the target region and the cell type in which this region was most likely to be functional. They then used haplotypespecific enhancer assays to validate the enhancer status of the predicted element, Hi-C to link the predicted enhancer to two target genes involved in early adipocyte differentiation, and expression quantitative-trait-locus (eQTL) analysis in primary human adipocytes from both risk-allele and non-risk-allele carriers to assess changes in gene expression. Finally, they restored the correct expression of the affected target genes in cells isolated from patients and a mouse model using CRISPRCas9 genome editing. In this case, a genetic variant was shown to be causally involved in a pathway for adipocyte thermogenesis regulation linked to pro-obesity and anti-obesity effects. There is no reason why the same P2F approach in combination with epigenome editing (as outlined below) should not work equally well for elucidating causal functions of epigenomic modifications and variants. Indeed, initial attempts to follow this strategy using a general pipeline are extremely encouraging 48 , but existing experimental and computational limitations, as well as currently unknown future challenges, will need to be overcome as the field moves forwards. Together with many other studies, these profiling and data integration efforts have resulted in a fantastic resource that already allows us to infer which marks and features may be functional and which forms the starting point for future analyses of causal function.
Towards genetic analysis of causality
Epigenomic profiling has aided the discovery of a plethora of coordinated chromatin changes that occur during development and disease. Data integration enables these candidate sites to be reduced to a subset with inferred function (FIG. 2) . However, the experimental validation of their relevance remains difficult. To some extent, genetic approaches have successfully provided evidence for the importance of chromatin marks. We discuss below two widely used approaches: genetic manipulation of the DNA domains underlying an epigenomic feature; and genetic manipulation of the enzymes that are responsible for the establishment or removal of these features.
Genetic manipulation of sites of chromatin marks or features. Individual epigenomic features can be removed through the manipulation of the underlying DNA sequence. Although it is possible to mutate or to delete single bases that harbour DNA modifications, this approach is not applicable to histone modifications or to larger epigenomic features. In many cases, entire genomic domains containing the feature of interest must be excised instead. Gene targeting has been an exceptionally successful approach to functionally link several epigenetic mechanisms (DNA methylation, chromatin insulation and non-coding transcription) to genomic imprinting [49] [50] [51] [52] . However, in most cases, genetic Nature Reviews | Genetics Currently used methods for epigenome editing of single marks or features can reveal causality, and future approaches using epigenetic screens (high-throughput epigenome editing) will enable us to identify novel functional marks on an epigenomic scale. manipulation provides only indirect evidence for causality (FIG. 2) . Functional consequences could also be attributed to the loss of the genomic DNA sequence rather than to the loss of the epigenomic feature.
Currently, genetic manipulation is often the only available option for conducting functional experiments (for example, see Fanuci et al. 53 ). Improved methods using targetable nucleases 54 have made it
Box 2 | Profile types and categories
The number of epigenomic marks and features that can be profiled is an inherently moving target. Consequently, the profile types and six categories shown here (see the figure) are incomplete and subject to change. The diagram of chromatin depicts common marks and features that are further grouped into six boxed categories that are listed on the right-hand side.
At the DNA level, modifications have been shown to occur at position C5 or N3 on cytosines and at position N6 on adenines and have been shown to be catalysed either enzymatically by DNA methyltransferases (DNMTs) for 5 mC or chemically for 3 mC. The mechanism of modification for 6 mA is still unknown. As part of an active demethylation pathway that is mediated by TET enzymes, 5 mC can be further modified by stepwise oxidation to 5hmC, 5 fC and 5caC. Because of their versatility, profiling of DNA modifications can be configured for multiple readouts, including differentially methylated positions (DMPs) and differentially methylated regions (DMRs), differentially variable positions (DVPs), partially methylated domains (PMDs) and blocks of co-methylation (COMETs) 133, 134 . At the histone level, 12 enzymatically catalysed modifications have been shown to occur at more than 130 post-transcriptional modification (PTM) sites at the tails of the four core histones (H2A, H2B, H3 and H4) and some 30 histone variants 135 . Recently, further modifications (H3K64ac and H3K122ac) were also observed in the globular domain of H3 and were shown by epigenome editing to define a new class of enhancers 136 . This illustrates that our current knowledge is far from complete. Despite their extraordinary variety, histone modifications are profiled by a single assay and readout (chromatin immunoprecipitation followed by sequencing (ChIP-seq)).
On the feature level, we distinguish three categories of structurally different features for which multiple profiling assays have been developed. For profiling nucleosome occupancy, DNase I footprinting (DNase-seq) has been the assay of choice in the past to identify cell type-specific regulatory elements but the assay for transposase-accessible chromatin sequencing (ATAC-seq) 137 is now becoming increasingly popular owing to its simpler workflow and its ability to be used with substantially fewer cells. Other nucleosome-occupancy techniques include formaldehyde-assisted isolation of regulatory elements followed by sequencing (FAIRE-seq), digital genomic footprinting (DGF), and nucleosome occupancy and methylome sequencing (NOME-seq). Different implementations of chromosome conformation capture assays (3C, 4C, 5C, Hi-C, chromatin interaction analysis with paired-end tag sequencing (ChIA-PET) and promoter capture Hi-C (PCHi-C)) are being used to connect enhancers to the promoters that they control, as well as for profiling of chromatin insulators that block those interactions. Especially when integrated with DNA and/or histone modification profiles, profiling with Hi-C 138 allows the segmentation of the epigenome into a variety of chromatin domains (for example, topologically associating domains (TADs)).
On the transcriptome level, many non-coding RNAs have been mapped, which in some cases can regulate gene expression 139 , and profiling of RNA modifications (for example, modifications occurring at position C5 or N3 on cytosines and at positions N1 and N6 on adenines) has not yet been systemically analysed. In the upper left-hand panel, base positions at which methylation has been found in DNA or RNA are marked in red.
Because of the complexity of combinatorial possibilities, there is currently no tissue or cell type for which all marks and features have been profiled. The largest collection of tissues and cell types for which at least nine core marks (shown in the upper right-hand panel) have been consistently profiled are those also referred to as International Human Epigenome Consortium (IHEC) reference epigenomes. easier to experimentally generate precise modifications of genetic sequence. Such approaches have been successfully used to interrogate enhancer regions [55] [56] [57] [58] [59] and to investigate the function of local chromatin architecture. As mentioned in BOX 2, local chromatin architecture can be profiled and segmented into topologically associating domains (TADs), the boundaries of which seem to be genetically defined by the orientation of CTCF-binding sites. Genetic inversion of CTCF-binding sites has been used to shift domain boundaries at the protocadherin gene cluster, leading to a re-configuration of enhancer-promoter interactions and to the reduced expression of some of the associated genes 60 . Similarly, a TAD structure at the EPHA4 locus was modified in a mouse model by introducing deletions and inversions that mimic those observed in patients with limb malformations 38 . Whereas in the examples mentioned above a handful of candidate features within small and well-defined regions (imprinted domains, individual enhancers or single topological domains such as TADs) were manipulated, most epigenomic profiles contain many hundreds or thousands of candidate marks that are distributed across the entire genome. A strategy for how genetic manipulation can nevertheless be used to interrogate many epigenomic candidate sites simultaneously was recently introduced 61 . Korkmaz et al. integrated different published chromatin profiles (for example, H3K4me2 and H3K27ac) and transcription factor-binding sites to generate a list of candidate active enhancers bound by p53. To reveal which of these enhancers was necessary for a specific function of p53, namely, the induction of oncogene-induced senescence, the authors introduced targeted mutations in 685 regions and found that, surprisingly, most of the p53-bound enhancers were dispensable for triggering senescence. Instead, the authors were able to show that only two genomic binding sites of p53 are mandatory for this disease-relevant mechanism 61 .
Genetic manipulation of chromatin-modifying enzymes. Despite being generally successful in attributing causal functions to genomic domains hosting epigenomic marks and features, the approaches mentioned Integration is achieved through two steps. First, missing data are imputed using profiles from the same sample (vertical red box) and/or closely related samples (horizontal red box). Currently, histone modification and transcription factor binding profiles are mostly used for imputation but there is no reason why other profiles cannot also be used. Second, additional, non-epigenomic data can be added as appropriate.
Although not the focus of this Review, such non-epigenomic data are equally important and include information on gene expression levels and transcription start sites (TSSs) derived from RNA sequencing (RNA-seq) studies. The entire data set per sample is then aggregated and segmented into chromatin states, ranging from two (as shown here by the filled red and green rectangles) to >50, depending on context and complexity 140 . Although most current epigenomic data have been derived from cell and tissue samples from healthy individuals, disease-relevant data from clinical samples and further integration with multi-omics data and pathways can be expected to follow soon, for example, as part of the recently established H2020 MultipleMS consortium for multiple sclerosis and the SYSCID consortium for chronic inflammatory diseases. For more details on the current strategy please refer to the fat-mass and obesity (FTO) example 45 given in the section on 'Data integration and interpretation'.
Zinc finger
A modular DNA-binding protein that can be engineered to bind to a sequence of choice.
Transcription activator-like effector (TALE). DNA-binding protein that has a modular architecture, with each module (~34 amino acids) recognizing a single nucleotide in a DNA sequence and that can therefore be engineered to bind to a DNA sequence of choice.
above cannot establish the relative contribution that the marks themselves make to the observed effects. A second experimental strategy using genetic targeting, namely, the deletion or mutation of chromatinmodifying enzymes, overcomes this drawback and thus has been most instrumental in demonstrating the participation of the enzymes per se in gene regulation. Epigenetic phenomena that are applicable to early embryogenesis-based or embryonic stem (ES) cell-based experiments (genomic imprinting and retro-transposon silencing, among others) are especially useful for attributing crucial roles to chromatin modifications, as these systems allow the study of the acute effect that the loss of certain chromatin marks (for example, H3K9 methyl ation and DNA methylation) has on the expression of candidate loci (imprinted genes and retro-transposons, respectively) [62] [63] [64] [65] 74, 75 ). Consequently, it is difficult to deduce the functional relevance of individual marks from the elimination of many thousands. Beyond the difficulties in distinguishing the local versus global epigenomic consequences when chromatin-modifying enzymes are mutated (or pharmacologically inhibited), there are more aspects to consider. Chromatin-modifying enzymes have a much larger range of substrates than is often presumed. Most, if not all, histone-modifying enzymes also have non-histone targets 76, 77 . Therefore, the resulting embryonic phenotypes cannot always be attributed to the misregulation of histone marks alone.
Embryonic lethality that arises from the germline depletion of genes can be circumvented by conditional knockouts. This strategy has been so successfully applied to chromatin-modifying enzymes that they can only be incompletely discussed here. The well-studied haematopoietic [78] [79] [80] [81] [82] , muscular 83 and cardiac 84, 85 systems are typical examples that have been used to show the crucial roles of DNA methylation [78] [79] [80] , H4K20 methylation 83 , H3K27 methylation 81, 82, 84 and histone acetylation 85 in somatic stem cell homeostasis, lineage specification and progression. However, it should also be mentioned that phenotypes detected in such studies are rarely driven by the deregulation of a multitude of genes as they are often surprisingly specific (for example, affecting only certain lineage choices 78, 81 or cellular phenotypes 83 ) and in some cases have even been rescued by normalizing the expression levels of single genes [82] [83] [84] . Although these observations of focused transcriptional consequences and specific phenotypes can in many cases be explained by the incomplete loss of chromatin marks or widespread compensation by redundant chromatin complexes, it could also indicate that only a small number of chromatin marks mediate functional effects that are large enough to cause cellular phenotypic changes and that those might strongly depend on the cellular context. Consistent with this idea is the fact that homeostatic cells often remain relatively unaffected by the pharmacological inhibition of chromatin-modifying enzymes, whereas many cancer cells show enhanced 'epigenetic vulnerability' (for a concise review see Dawson et al. 86 ). Another example is the finding that, in vitro, even the global loss of canonical epigenetic marks does not necessarily result in major transcriptomic changes. The (almost) complete loss of DNA methylation 87 , H3K27me3 (REF. 88) or an artificial induction of H3K4me3 marks 89 in ES cells, for example, results only in minor transcriptional changes, despite affecting their differentiating progeny. Taken together, these data indicate that a majority of epigenetic marks may not have decisive roles in stable cell populations and that the causality of chromatin marks may only be revealed when accompanied by major cellular transitions such as differentiation, reprogramming and transformation. An alternative (but not mutually exclusive) explanation would be that many chromatin marks in the epigenome have opposing causal roles, which are often 'cancelled out' when marks are globally altered but which may result in more pronounced phenotypes when the manipulation of chromatin modifications is restricted to a few individual loci. In summary, the genetic manipulation of chromatin-modifying enzymes has been crucial to implicating their causal involvement in many biological processes; however, the functional involvement of individual chromatin marks can mostly still only be inferred (FIG. 2) .
Site-specific epigenome editing Recruitment of chromatin-modifying enzymes to specific loci. The genetic experiments described above indicate that only a small proportion of marks detected in epigenomic profiles may have direct causal roles (FIG. 2) . Consequently, new experimental approaches that are able to directly test the causal function of individual epigenetic marks are in high demand. Several new approaches are currently emer ging, including the exploitation of naturally occurring or engineered histone mutations 90, 91 and targetable chromatin remodelers 92 . Another approach is the fusion of chromatin-modifying enzymes (or catalytic domains) to targetable DNA-binding domains, which has made it possible to change single chromatin marks at particular genomic sites. This constitutes a substantial technological advance, as it is now possible to interrogate the function of individual marks instead of removing the underlying DNA sequences or all instances of a particular mark across the entire genome by genetic or pharmacological approaches. There is now a range of systems that allow the targeting of a chromatinmodifying enzyme to specific DNA sequences by fusing it to either a zinc finger, a transcription activator-like effector (TALE) or a catalytically inactive variant of the Cas9 (CRISPR-associated protein 9). Useful for genome engineering because it can be guided (by a guide RNA) to a particular site in the genome where it makes a DNA double-strand break.
dCas9
The nuclease-dead version of Cas9, which can no longer produce DNA double-strand breaks.
Guide RNA (gRNA). An artificial fusion of CRISPR RNA (crRNA) and transactivating crRNA (tracrRNA) used to target the Cas9 protein to a target site in the genome.
bacterial Cas9 nuclease (dCas9). Specifying the genomic target sequence using zinc finger or TALE architectures involves assembling multiple repetitive protein domains that each recognize a particular DNA base in the target sequence. By contrast, the CRISPR-Cas system can be targeted to a precise genomic location by specifying the base sequence of part of a synthetic RNA known as a guide RNA (gRNA). Remarkably, Cas9 is able to target genomic sites, even when they are functionally silenced or structurally condensed, although this influences the dynamics of DNA recognition 93 . It is easier and faster to generate large numbers of gRNAs that target different sequences than it is to assemble a large number of different zinc finger or TALE domains. The main advantage of the CRISPR-Cas system for epigenome editing thus lies in the ease of generating targeting constructs and its potential for multiplexing.
Using these platforms to target chromatinmodifying enzymatic domains to particular sites in the genome enables the testing of whether individual chromatin marks have causal effects on gene expression (as illustrated in FIG. 4a) . In addition to more general transcriptional transactivator and repressor proteins 94 , a range of chromatin-modifying enzymes have already been attached to DNA-binding domains and shown to successfully add or remove chromatin marks at the target sites (TABLE 1) . Collectively, these pioneering studies have shown that the catalytic domains of chromatinmodifying enzymes can be sufficient to induce transcriptional changes when directed to specific target sites. Adequate controls were included in most of these studies, including catalytic mutants which ensured that the observed effect is due to enzymatic activity and not merely due to chromatin binding. For example, demethy lation of several sites in the RHOXF2 promoter leads to the transcriptional upregulation of this gene 95 . Similarly, a dCas9-p300 histone acetyltransferase fusion has been used to activate the transcription of MYOD and OCT4 from proximal promoters and distal enhancers. In many cases, the induction of mRNA production achieved with dCas9-p300 is stronger than that achieved with a classical transactivator domain without enzymatic activities (VP64) at the same site 94, 96 . Additionally, lysine demethylase LSD1 has been shown to silence genes when targeted to known enhancer regions 14, 97 , whereas various targetable constructs of the DNMT3A DNA methyltransferase can decrease transcript levels when targeted to promoters [98] [99] [100] . Thus, targetable chromatin modifiers have been used both to upregulate and to downregulate mRNA levels, providing direct evidence that chromatin modifiers can regu late transcription. Whether the observed effects are exclusively mediated through epigenomic marks or whether local modifications of other chromatin proteins can sometimes contribute 101 has yet to be firmly established. Furthermore, effects on transcription are detected following the modification of some, but not all, targeted sites. This indicates inherent differences in the regulatory potential of genomic loci and, consistent with results from genetic experiments, that certain chromatin marks may only be functionally relevant at a subset of sites at which they occur. To further investigate this, it will be necessary to study how the catalytic activity of the chromatin modifier at a particular site affects transcription and whether the engineered chromatin changes recruit known 'readers' of chromatin marks.
As discussed above, the term 'function' can take different meanings ranging from inferred to causal, whereby causal function could manifest itself in several ways. Some epigenomic features might be dominant in their effect (for example, directly affecting RNA polymerase activities), whereas others might be dependent on certain pre-requisites to reveal a functional involvement (for example, transcriptional priming: poising the cellular response spectrum by forming a transcription factor binding platform) 19, 102 . Thus, in some cases (and quite similar to most other biological mechanisms), the function of an epigenomic feature could depend on the cell type, culture condition or the developmental window studied. Furthermore, causal effects could also reveal themselves on several levels, as a change in transcript level, protein level or cellular phenotype. It is often difficult to judge whether statistically significant but sometimes relatively small engineered changes in transcript levels are biologically relevant. It is encouraging that several studies have already achieved changes in protein level through epigenome editing 97, 98, [103] [104] [105] . Ultimately, however, it will be important to directly test whether engineered chromatin modifiers can influence cellular or organismal phenotypes. Some reports have made such a connection already, showing, for example, that the addition or removal of single chromatin marks is sufficient to alter cell proliferation, colony-forming ability of cancer cells 98 , the self-renewal of pluripotent stem cells 97 and even addiction-related behaviour in living mice 103 . One important question that remains unanswered is how common such functional marks are and whether engineered changes can be sustained by cells and mitotically inherited. Although DNA methylation is thought of as both a heritable and a stable mark, there is emerging evidence that cells may in fact counteract engineered changes. Engineered DNA methylation marks have been observed in some studies to decrease to background levels in vitro 106, 107 , indicating that they are either actively or passively lost; however, in another report, engineered marks were found to persist 108 . As the targeted sites differed (and in the study with the persistent marks, they were located on a human artificial chromosome) it is possible that endogenous chromatin 'context' determines whether an engineered change can be maintained, but this requires further investigation. If engineered changes are found to be transient -and this may need to be established independently for each type of chromatin modification at each targeted sitenegative results with regard to functional effects need to be examined with care. Expression of the targetable chromatin modifier, engineered modifications, transcriptional and phenotypic changes should be monitored over time. One recent study monitored silencing up to 50 days after transfection and showed stable gene silencing using a combination of transiently expressed repressors (KRAB, DNMT3A and DNMT3L) targeted either through dCas9 or through TALE DNA-binding domains to the endogenous B2M locus in K562 cells 104 . The maintenance of silencing seemed to be dependent on DNA methylation at this locus, as treatment with 5-azacytidine or targeted demethylation with a dCas9-TET1 construct re-activated the locus in a proportion of cells, whereas targeting with dCas9-p300, the transcriptional activator dCas9-VP160 or treatment with interferon-γ had no effect. Nature Reviews | Genetics (dCas9) ). The enzymatic activity of the chromatin modifier is directed towards a particular DNA sequence where it can either add or remove chromatin marks from histones or DNA depending on the nature of the chromatin modifier. This system allows the investigation of how the editing of a mark at a particular site affects the expression of associated genes. Readouts can be at the level of RNA, protein or phenotype (as shown). b | Illustration of how targeted epigenome editing can be used to build a hierarchy of functional marks. Various different chromatin modifiers (shown in different colours) are fused to the same DNA-binding domain and targeted to the same site. The effect of the engineered chromatin modification on associated genes can be measured to establish a hierarchy of chromatin features. Upward-pointing and downward-pointing bell-shaped curves represent upregulation and downregulation of the target gene, respectively. c | Using epigenome editing allows the identification of chromatin modifications that affect cellular phenotypes. Prior knowledge about the genes involved in regulating particular phenotypes and the location of regulatory elements can be used to design pooled guide RNA (gRNA) libraries that enable targeted screens. If particular gRNAs target the chromatin modifier to functional sites, phenotypic changes are induced; this allows the selection of the cells of interest, determination of gRNA sequences and hence the identification of the regulatory element where an altered epigenomic state controls the phenotype of interest.
Investigating quantitative contributions and hierarchies of regulatory epigenetic marks. Now that tools to manipulate individual chromatin marks have become widely available, the time has come to move on from qualitative descriptions (such as 'silencing' or 'activating') to comprehensively quantify the contribution of individual marks in defining endogenous transcriptional states. Therefore, it would be useful to establish a hierarchical order of these marks; that is, to elucidate which functional chromatin marks are primary triggers (influencing other epigenomic features) and which marks usually occur as secondary consequences. In this way, it would be possible to pinpoint the proportion of transcription that is strictly defined by chromatin features, how other gene-regulatory mechanisms (transcription factors, topological structure and non-coding transcription) are interlinked and where the molecular switches can be found that functionally turn genes on and off. To quantify the individual contribution of different epigenetic modifications, many different types of engineered chromatin marks should be directly compared (FIG. 4b) . To this end, epigenome editing approaches should not solely concentrate on re-assessing the importance of well-studied chromatin marks but should instead include some of those marks and features that have so far been less comprehensively analysed (depicted in BOX 2) . However, this will require the swift development of a series of new engineering tools. In yeast, the first important steps in this direction have already been taken 109 . In this organism, more than 100 different chromatin factors were fused to the same zinc finger DNA-binding domain targeting the promoter of a reporter gene. Some of the targeted proteins were found to act as activators, whereas others acted as inhibitors, which allowed subsequent ranking based on effect size; that is, changes in protein expression in response to targeted chromatin modification 109 . Studies in mammalian cells have not yet been as comprehensive but some recent publications have followed a similar strategy to compare the effects of a series of chromatin domains 110 and modifications 108 on candidate genes in mammalian cells 94 . Such approaches will be the basis for elucidating the hierarchical order of chromatin marks. Targeting more than one chromatin modification to the same locus will allow the elucidation of which marks are causing others to change and which are functionally dominant, antagonistic, additive and synergistic. Sequential expression of dCas9-chromatin-modifier constructs will show whether the timing of modifications is important in establishing chromatin states and, in combination with overexpression and knockdown constructs, will pinpoint the relationship of marks with other gene-regulatory mechanisms (such as interplay with transcription factors). Thus, expanding the molecular toolbox of epi genome editing will be of lasting benefit, owing to the large amount of possible questions to tackle in the near future.
Epigenome editing of higher-order chromatin architecture. Local chromatin architecture has been extensively manipulated by genomic targeting through deletions or mutation of regulatory regions, insulators and border elements (for example, see REFS 38, 49, 111, 112) . Strategies are currently emerging that can alter domain boundaries without affecting the underlying genomic DNA sequence. Although targetable CTCF proteins have not yet been reported, a zinc finger-LDB1 fusion has been used to target the inactive β-globin locus in an erythroblast cell line lacking GATA1 (REF. 113 ). Binding of LDB1 induced the formation of a chromatin loop between the promoter and a locus control region and was sufficient to activate the transcription of β-globin, although the expression levels did not reach wild-type levels. A similar approach has been used to activate the expression of developmentally silenced fetal globin genes in mouse and human erythroid cells, which might have translational value for the treatment of sickle-cell anaemia 113 .
A vision for high-throughput epigenetic screens. It has now been convincingly demonstrated that particular chromatin modifications can affect the expression of reporter loci and, in some cases, even endogenous genes. One of the currently pressing questions in epigenetics is how much of the genome will be controllable in a similar way. The availability of a wide range of epigenome editing tools could be used in the future to screen for individual epigenomic marks that are either necessary or sufficient for specific cellular phenotypes (FIG. 4c) . This would require appropriate libraries of gRNAs, each targeting dCas9-chromatin-modifying enzymes to different genomic sites. In order to avoid screening complete genomes, knowledge gained from epigenomic profiles should be integrated into library design. For example, designing gRNA libraries that focus on informative regions that have been identified from integrative ana lysis of epigenomic profiles would greatly reduce the complexity of libraries and would thus enhance the power of such epigenomic screens. As outlined in FIG. 4c , such pooled screens will enable the identification of the subset of causal epigenetic marks among the many with inferred function. gRNA libraries representing loci identified in epigenomic profiles would be introduced into cells expressing the relevant dCas9-modifier fusion. Cells that responded to an individual modification with a suspected phenotypic change will be separated from the bulk population (through selection, fluorescence-activated cell sorting (FACS) or cellular behaviour) and used to gain information about the individual gRNAs the cells received. It is difficult to predict which cellular phenotypes will be most susceptible to these approaches, but one way forwards would be to start with the cellular phenotypes that are clearly epigenetic, easy to quantify and ideally reversible (for example, cell identity, cell cycle control and migration).
In principle, epigenetic screens are already feasible. For example, rather than genetically mutating a large number of enhancers through CRISPR-based genetic screening 61 , epigenome editing tools could be used to manipulate chromatin modifications at these sites. A small-scale epigenetic screen such as this has already been conducted. Kearns et al. used published profiles of ES-and epiblast-like cells (EpiLCs) to generate a list of candidate enhancers with potential roles in pluripotency. Targeting dCas9-LSD1 to one of these active enhancers mediated H3K4 demethylation and abrogated the transcription of associated genes 97 , and the authors then used this system to screen eight candidate enhancers to investigate the effect of H3K4 demethylation on ESC self-renewal 97 . Scaling up such epigenome editing approaches to epigenome-wide screens has the potential to reveal many (and eventually all) epigenetic marks and features that have causal roles in a given cellular phenotype (FIG. 4c) .
To make epigenome editing universally applicable, several issues have yet to be resolved: first and foremost, information about the distribution of the majority of chromatin features is still missing. Only a small minority of epigenomic features has been profiled, and some of the profiling technologies used have since become outdated and/or have evolved (for example, epigenomics on the single-cell level) 114 , indicating a continued need for profiling efforts. Moreover, the toolset of efficient dCas9-chromatin-modifier fusion proteins needs to be expanded. There is, for example, no current validated tool for the successful addition or removal of H3K27 methylation, which is one of the most frequently profiled chromatin marks in human cells. Furthermore, gRNA libraries specifically targeting regions that harbour particular chromatin modifications are not yet available. However, simple methods for the generation of ultra-high-complexity or even genome-wide gRNA libraries have already been established 115, 116 . Finally, to make the most of the new molecular tools discussed in this Review, reliable in vitro models or in vivo approaches that allow the assessment (and selection) of induced pheno typic changes need to be developed 103 . Considering the rapid progression of CRISPR-based technology during recent years it is conceivable that comprehensive functional interrogation of chromatin marks and features could become a common component of epigenomic-profiling studies in the near future.
Conclusions
In this Review, we have traced some of the seminal studies and approaches that have been leading the way towards the functional analysis of epigenomic marks and features, which remains one of the main challenges for epigenomics. Based on current evidence, the key innovation to deliver this breakthrough will almost certainly be based on epigenome editing and, in particular, on the ability to conduct epigenome-wide screens to identify causal chromatin features from the myriad of features with inferred function identified through epigenomic profiling and data integration. Returning to the analogy of an epigenetic landscape, epigenomic engineering promises to turn the static landscape, as depicted by Waddington, into a dynamic environment, as illustrated by a contemporary animation (FIG. 1b; see Supplementary information S1 (movie)) created by the resident artists of EpiGeneSys (see Further information), the European Network of Excellence for Epigenetics and Systems Biology. In the context of this Review, the pulling of the strings to alter the contours of the landscape represents the approaches discussed here to screen for chromatin marks that causally influence cellular fate in health and disease. On the basis of the tremendous progress made to date, it is perhaps not surprising that expectations are running high to translate any fledgling new insights into novel treatments. Although epigenetic marks and drugs are already in clinical use as biomarkers and treatments, respectively, epigenome editing has not yet been used therapeutically. In addition to functional candidates and technical improvements, this step would require ethical considerations similar to those currently discussed for genome-editing technology 117 . With these promising developments in mind, does this mean that epigenomic profiling is essentially completed and a thing of the past? Certainly not, because new marks and features are still being discovered and new and improved profiling technologies are still being developed. It will, however, be interesting to explore which type of profiling turns out to be the most informative for which field of research and, in particular, for the discovery of causal functions hidden in chromatin.
